Glaxosmithkline Pharmaceuticals Ltd.

GLAXO

₹2682.8

2.45% (64.2)

Market Cap

₹45,492 Cr.

P/E

47.87

Key Ratios

Edit Ratio's

Market cap

45,492 Cr

47.87

Prom Holding

75.00 %

ROE (%)

47.54

ROCE (%)

60.93

Div Yield (%)

2.01

Sales

3,739 Cr

OPM (%)

32.03 %

Debt to Equity

Edit Ratio's

About

GlaxoSmithKline Pharmaceuticals Limited focuses on research, manufacturing, and providing a wi… Read more

Low

1921

52W Range

High

3516

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

0 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

5.97 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

1.14 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

13.90 %

(as of Mar 22)

Source/Historic

Augmentin - Market Share

3.40 %

(as of Mar 22)

Source/Historic

Betnesol - Market Share

5.80 %

(as of Mar 22)

Source/Historic

Betnovate C - Market Share

6.10 %

(as of Mar 22)

Source/Historic

Betnovate N - Market Share

0.64 %

(as of Nov 21)

Historic

Blood Related - Market Share

9.30 %

(as of Mar 22)

Source/Historic

Calpol - Market Share

0.08 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

5.60 %

(as of Mar 22)

Source/Historic

Ceftum - Market Share

10.50 %

(as of Nov 21)

Historic

Dermatology - Market Share

5.20 %

(as of Mar 22)

Source/Historic

Eltroxin - Market Share

11.80 %

(as of Nov 21)

Historic

Endocrinology - Market Share

0.09 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

0.24 %

(as of Nov 21)

Historic

Gynecology - Market Share

0.01 %

(as of May 20)

Historic

Neurological - Market Share

0.79 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

3.25 %

(as of Nov 21)

Historic

Pain - Market Share

2.60 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

2.23 %

(as of Nov 21)

Historic

Respiratory - Market Share

3 %

(as of Nov 21)

Historic

Stomatological - Market Share

2.80 %

(as of Mar 22)

Source/Historic

Synflorix - Market Share

6.20 %

(as of Mar 22)

Source/Historic

T Bact - Market Share

1.21 %

(as of Jan 20)

Historic

Urology - Market Share

24.13 %

(as of Jul 22)

Historic

Vaccines - Market Share

1.92 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

5.20 %

(as of Mar 19)

Source/Historic

Zinetac - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up

Acute vs Chronic

Operational Metrics

Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Augmentin

Betnesol

Calpol

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

FAQs on Glaxosmithkline Pharmaceuticals Ltd. Business

What does Glaxosmithkline Phar do?

Glaxosmithkline Pharmaceuticals Limited offers a broad range of medicines and vaccines with commercial leadership in anti-infectives and dermatology, focusing on immune science, genetics, and advanced technologies. They are leaders in the private segment in India.

Who are the competitors of Glaxosmithkline Phar?

Glaxosmithkline Phar major competitors are Glenmark Pharma, Ipca Laboratories, Gland Pharma, Ajanta Pharma, Abbott India, JB Chem & Pharma, Astrazeneca Pharma I.
Market Cap of Glaxosmithkline Phar is ₹44,456 Crs.
While the median market cap of its peers are ₹31,790 Crs.

Is Glaxosmithkline Phar financially stable compared to its competitors?

Glaxosmithkline Phar seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep	Mar Jun Sep Dec	Dec
Investor Presentation	May Aug	Mar Jun		Jun	Jun		Dec				Mar
Conference Call	Mar Jun	Mar Jun Sep Dec	Dec	Jun Sep
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Pharmaceuticals

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Glaxosmithkline Pharmaceuticals Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

10 Yes

2 Neutral

5 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Revenue Recognition

Promoter Holding

Depreciation Effect

Retail Holding

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Debt

ROCE Strength

Balance Sheet Strength

Current vs Historic Valuation

Sales Growth

Margin Stability

Market Share

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Acute vs Chronic

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Brands

Corporate Actions

FAQs on Glaxosmithkline Pharmaceuticals Ltd. Business

What does Glaxosmithkline Phar do?

Who are the competitors of Glaxosmithkline Phar?

Is Glaxosmithkline Phar financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE